TG Therapeutics Announces Phase I Study of Novel BTK inhibitor, TG-1701, in Patients with Relapsed or Refractory B-cell Malignancies is Open for Enrollment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| TG THERAP (NASDAQ: TGTX) | Delayed: 53.16 -0.04 (0.08%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $53.20 | 52 Week High | $14.87 | |||
| Open | $53.02 | 52 Week Low | $4.90 | |||
| Day High | $53.70 | P/E | N/A | |||
| Day Low | $52.53 | EPS | $-0.67 | |||
| Volume | 1,289,186 | |||||
